Jump to content

Hang onto your hat: Sclero Forums Upgrade May 14-21, 2017!! The Forums will be offline for up to 4 days, and then will return with an entirely new look and feel.


Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review.


  • Please log in to reply
1 reply to this topic

#1 Joelf


    Star Ruby Member

  • ISN Root Admin
  • PipPipPipPipPipPipPipPipPipPipPipPipPip
  • 4,902 posts
  • Location:West Sussex

Posted 13 July 2015 - 08:13 AM

Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review.


Mycophenolate-associated gastrointestinal adverse events are common in SSc, but not severe enough to preclude its use and it may be effective in improving or stabilizing interstitial lung disease and skin involvement. PubMed, PLoS One, 2015 May 1;10(5):e0124205. (Also see Immunosuppressants)


This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Jo Frowde
ISN Assistant Webmaster
SD World Webmaster
ISN Sclero Forums Manager
ISN News Manager
ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)

#2 miocean


    Senior Gold Member

  • Members
  • PipPipPipPipPipPipPipPip
  • 920 posts
  • Location:NJ

Posted 13 July 2015 - 02:43 PM

I have been on myfortic or mycophenolate acid since my kidney transplant in 2010. I had almost immediate improvements in skin score and my lungs were stable until 2013. Since then there has been an increase in fibrosis including honeycombing and I have needed to use oxygen. Although all tests are stable since 2013 I have increased shortness of breath, even with the oxygen. I have suffered with horrible diarrhea since my transplant and right now my dose is reduced until I recover from this latest bout which landed me in the hospital with dehydration and acute renal failure. The dose will be increased as I am able to tolerate it as it is known to help stabilize lung disease.



ISN Artist